Needham Reiterates Liquidia (LQDA) Buy Recommendation
Fintel reports that on July 31, 2023, Needham reiterated coverage of Liquidia (NASDAQ:LQDA) with a Buy recommendation.
Analyst Price Forecast Suggests 87.78% Upside
As of July 6, 2023, the average one-year price target for Liquidia is 14.57. The forecasts range from a low of 3.03 to a high of $21.00. The average price target represents an increase of 87.78% from its latest reported closing price of 7.76.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Liquidia is 16MM, a decrease of 6.87%. The projected annual non-GAAP EPS is -0.73.
What is the Fund Sentiment?
There are 208 funds or institutions reporting positions in Liquidia. This is an increase of 6 owner(s) or 2.97% in the last quarter. Average portfolio weight of all funds dedicated to LQDA is 0.27%, a decrease of 16.24%. Total shares owned by institutions decreased in the last three months by 3.00% to 30,458K shares. 
The put/call ratio of LQDA is 0.44, indicating a bullish outlook.
What are Other Shareholders Doing?
Caligan Partners holds 9,244K shares representing 14.28% ownership of the company. No change in the last quarter.
KOMP - SPDR S&P Kensho New Economies Composite ETF holds 1,787K shares representing 2.76% ownership of the company. In it's prior filing, the firm reported owning 1,728K shares, representing an increase of 3.34%. The firm increased its portfolio allocation in LQDA by 1.08% over the last quarter.
Kynam Capital Management holds 1,642K shares representing 2.54% ownership of the company. In it's prior filing, the firm reported owning 1,753K shares, representing a decrease of 6.73%. The firm decreased its portfolio allocation in LQDA by 14.47% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,531K shares representing 2.37% ownership of the company. No change in the last quarter.
IWM - iShares Russell 2000 ETF holds 1,041K shares representing 1.61% ownership of the company. In it's prior filing, the firm reported owning 1,083K shares, representing a decrease of 3.98%. The firm increased its portfolio allocation in LQDA by 8.99% over the last quarter.
Liquidia Background Information
(This description is provided by the company.)
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT technology. The Company operates through two subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies is developing two product candidates: LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH), and LIQ865, an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain for three to five days after a procedure. Liquidia PAH, LLC provides commercialization for rare disease pharmaceutical products, such as Treprostinil Injection, Sandoz Inc.'s first-to-file, generic treprostinil for PAH.
Additional reading:
- Confidential Information
- U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation
- Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America
- Fourth Amendment to Promotion Agreement, dated as of March 10, 2023, by and between Liquidia PAH, LLC and Sandoz Inc.
- Research License Agreement, dated as of March 31, 2023, by and between Liquidia Technologies, Inc. and Glaxo Group Limited.
This story originally appeared on Fintel.